Brilacidin: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 120 patientsc19early.org

Brilacidin for COVID-19

Serious outcome risk
Brilacidin
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Mortality (1)0%
RCTs (1)0%
Late (1)0%
00.511.5+
← Brilacidin
reduces riskIncreased
risk →
c19early.org
October 2026

Brilacidin COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Innovati.. (DB RCT)0%1.00 · 0.26–3.81death4/604/60
Late treatment0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →
c19early.org
October 2026

Brilacidin COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Innovati.. (DB RCT)0%1.00 · 0.26–3.814/604/60
Late treatment0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →
c19early.org
October 2026

Brilacidin COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Innovati.. (DB RCT)0%1.00 · 0.26–3.81death4/604/60
Late treatment0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →
c19early.org
October 2026

Brilacidin COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Innovati.. (DB RCT)−20%1.20 · 0.39–3.72no recov.6/605/60
Late treatment−20%1.20 · 0.39–3.726/605/6020% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.76
All studies−20%1.20 · 0.39–3.726/605/6020% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.7600.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →
c19early.org
October 2026

Brilacidin COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Innovati.. (DB RCT)0%1.00 · 0.26–3.81death4/604/60
Late treatment0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →
c19early.org
October 2026

Brilacidin COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Innovati.. (DB RCT)0%1.00 · 0.26–3.814/604/60
Late treatment0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.814/604/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →
c19early.org
October 2026

Brilacidin COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Innovati.. (DB RCT)0%1.00 · 0.26–3.81death4/604/60 Innovati.. (DB RCT)−33%1.33 · 0.31–5.70death4/603/60 Innovati.. (DB RCT)−33%1.33 · 0.31–5.70death/int.4/603/60 Innovati.. (DB RCT)−20%1.20 · 0.39–3.72no recov.6/605/60 Innovati.. (DB RCT)−8%1.08 · 0.84–1.39recov. time44 (n)60 (n)
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Brilacidin
reduces riskBrilacidin
increases risk →